Passage Bio Implements 1-for-20 Reverse Stock Split to Comply with Nasdaq Requirement

Passage Bio, Inc. has approved a reverse stock split of outstanding shares at a ratio of 1-for-20 effective July 14, 2025, to comply with Nasdaq’s bid price requirement. Shareholders approved the split reducing outstanding shares from 62,405,898 to 3,120,295. Adjustments will be made to exercise prices and shares underlying equity awards. Stockholders do not need to take action, and fractional shares will be rounded up. Passage Bio focuses on genetic medicines for neurodegenerative diseases, with lead product candidate PBFT02 targeting frontotemporal dementia. For more information, visit passagebio.com.

Read more at GlobeNewswire: Passage Bio Announces 1-for-20 Reverse Stock Split